FTY720: Altered lymphocyte traffic results in allograft protection

Transplantation

Volumn 72, Issue 5, 2001, Pages 764-769

  Brinkmann, Volker ^a   Pinschewer, Daniel D ^b   Feng, Lili ^c   Chen, Shizhong ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; FINGOLIMOD; IMMUNOMODULATING AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ALLOGRAFT; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; DRUG SAFETY; GRAFT REJECTION; HUMAN; IMMUNOMODULATION; LYMPHOCYTE; LYMPHOCYTE MIGRATION; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; REVIEW;

EID: 0035884709     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200109150-00002     Document Type: Review

References (52)

1. Immunosuppressants: Cellular and molecular mechanisms of action
2. FTY720 immunosuppression impairs effector T-cell peripheral homing without affecting induction, expansion, and memory
3. FTY720: A novel transplantation drug that modulates lymphocyte traffic rather than activation
4. Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immunosuppressant, FTY720
5. Simple compounds, 2-alkyl-2-amino-1,3-propanediols have potent immunosuppressive activity
6. Synthesis and biological evaluation of 2,2-disubstituted 2-aminoethanols: Analogues of FTY720
7. Synthesis and immunosuppressive activity of 2-substituted2-aminopropane-1,3-diols and 2-aminoethanols
8. The identification of myriocin-binding proteins
9. Enhanced chemokine-dependent lymphocyte chemotaxis by FTY720 results in immunosuppression
10. FTY720, a novel immunosuppressant possessing unique mechanisms. II. FTY720 prolongs skin allograft survival by decreasing T-cell infiltration into grafts but not cytokine production in vivo
11. FTY720, a new immunosuppressant, promotes long term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation
12. Human safety and pharmacology of FTY720
13. Human pharmacokinetics of FTY720
14. Safety and pharmacodynamics of multiple doses of FTY720
15. FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with CsA in rats
16. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing
17. FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporin A
18. Immunosuppressive effect of a new drug, FTY720, on lymphocyte responses in vitro and cardiac allograft survival in rats
19. Induction of lymphocyte apoptosis and prolongation of allograft survival by FTY720
20. Immunosuppressive effects of FTY720 alone or in combination with cyclosporine and/or sirolimus
21. Effect of pretreatment with FTY720 and cyclosporin on ischaemia-reperfusion injury of the liver in rats
22. Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720: Effect of monotherapy and combined treatment with conventional drugs
23. Immunosuppressive therapy using FTY720 combined with tacrolimus in rat liver transplantation
24. Prevention of graft rejection and graft-versus-host reaction by a novel immunosuppressant, FTY720, in rat small bowel transplantation
25. Effect of peritransplant FTY720 alone or in combination with post-transplant tacrolimus in a rat model of cardiac allotransplantation
26. FTY720 compares with FK506 as rescue therapy in rat heterotopic cardiac transplantation
27. An immunosuppressive regimen using FTY720 combined with cyclosporin in canine kidney transplantation
28. Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine
29. Synergistic interaction of FTY720 with cyclosporin or sirolimus to prolong heart allograft survival
30. The peripheral lymphocyte count predicts graft survival in DA to Lewis heterotopic heart transplantation treated with FTY720 and SDZ RAD
31. FTY720 is efficacious in monkey kidney transplantation
32. Combination effect of tacrolimus and FTY720 in liver transplantation in rats
33. FTY720, a novel immunosuppressant, shows a synergistic effect in combination with FK506 in rat allograft models
34. Chronic rejection: Risk factors, regulation, and possible sites of therapeutic intervention
35. Basic science aspects of chronic rejection: Induction of protective genes to prevent development of transplant arteriosclerosis
36. Prevention of graft vessel disease by combined FTY720 and Cyclosporin A treatment in the DA to Lewis rat carotid artery transplantation model
37. Islet transplantation
38. Islet transplantation in seven patients with type 1 diabetes mellitus using aglucocorticoid-free immunosuppressive regimen
39. Effect of a new immunosuppressive agent, FTY720, on survival of islet allografts
40. FTY720, a novel immunosuppressive agent with insulinotropic activity, prolongs graft survival in a mouse islet transplantation model
41. Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats
42. FTY720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes
43. Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats
44. The in vivo induction of lymphocyte apoptosis in MRL-lpr/lpr mice treated with FTY720
45. Differential activation of c-Jun NH2-terminal kinase and p38 pathways during FTY720-induced apoptosis of T lymphocytes that is suppressed by the extracellular signal-regulated kinase pathway
46. FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression
47. FTY720 blocks allograft rejection by homing of lymphocytes in vivo
48. The role of chemokine receptors in primary, effector, and memory immune responses
49. Sphingosine-1-phosphate signaling via the EDG-1 family of G-protein-coupled receptors
50. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs
51. A lymphoid tissue-specific receptor, EDG-6, with potential immune modulatory functions mediated by extracellular lysolipids
52. FTY720 combined with Neoral and corticosteroids is effective and safe in prevention of acute rejection in renal allograft recipients